Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 98.
360. lappuse
... Proceed as directed in paragraph ( a ) of this section , except di- lute sample with 0.05N sodium hydrox- ide ( diluent 9 ) . ( g ) Method 7. Proceed as directed in paragraph ( a ) of this section , except di- lute sample with sodium ...
... Proceed as directed in paragraph ( a ) of this section , except di- lute sample with 0.05N sodium hydrox- ide ( diluent 9 ) . ( g ) Method 7. Proceed as directed in paragraph ( a ) of this section , except di- lute sample with sodium ...
376. lappuse
... Proceed as directed in paragraph ( a ) of this section , except dry the sample at a temperature of 110 ° C. and a pressure of 5 millimeters of mercury or less for 3 hours . ( d ) Method 4. Proceed as directed in paragraph ( a ) of this ...
... Proceed as directed in paragraph ( a ) of this section , except dry the sample at a temperature of 110 ° C. and a pressure of 5 millimeters of mercury or less for 3 hours . ( d ) Method 4. Proceed as directed in paragraph ( a ) of this ...
464. lappuse
... Proceed as directed in para- graph ( a ) ( 2 ) of this section , except pre- pare the sample as follows : Place a rep- resentative portion of the sample ( usu- ally approximately 1 gram , accurately weighed ) or the entire contents of a ...
... Proceed as directed in para- graph ( a ) ( 2 ) of this section , except pre- pare the sample as follows : Place a rep- resentative portion of the sample ( usu- ally approximately 1 gram , accurately weighed ) or the entire contents of a ...
466. lappuse
... Proceed as directed in § 436.20 , using the method described in paragraph ( e ) ( 2 ) of that section , except use medium C in lieu of medium A , and medium F in lieu of medium E. During the period of incubation , shake the tubes at ...
... Proceed as directed in § 436.20 , using the method described in paragraph ( e ) ( 2 ) of that section , except use medium C in lieu of medium A , and medium F in lieu of medium E. During the period of incubation , shake the tubes at ...
468. lappuse
... directed in §440.80a ( b ) ( 1 ) of this chapter , except $ 440.80a ( b ) ( 1 ) ( iv ) and ( ix ) of this chapter . If the iodometric chemical assay is used , proceed as di- rected in § 440.80a ( b ) ( 5 ) ( iv ) ( a ) of this chapter ...
... directed in §440.80a ( b ) ( 1 ) of this chapter , except $ 440.80a ( b ) ( 1 ) ( iv ) and ( ix ) of this chapter . If the iodometric chemical assay is used , proceed as di- rected in § 440.80a ( b ) ( 5 ) ( iv ) ( a ) of this chapter ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning